A fungal-based bio-control solution using the hyperparasitic pathogen Sphaeropsis visci to combat European mistletoe (Viscum album), a hemiparasitic plant causing significant economic losses in forestry. This environmentally friendly alternative enables mistletoe management in sensitive areas such as urban environments and locations near schools where chemical pesticides cannot be used.
European mistletoe (Viscum album L.) is a hemiparasitic plant that causes substantial economic losses in forestry worldwide and contributes to forest decline alongside climate change. Currently, the only effective control method is mechanical removal by cutting infected branches, which is impractical in many settings.
This research proposes developing a mycopesticide based on Sphaeropsis visci, a fungal plant pathogen that causes leaf spot disease in European mistletoe. The fungus spreads across leaves, branches, and berries, causing the entire shrub to become dark yellow and necrotic within a few months of inoculation. As a biological control method, it offers an environmentally friendly alternative to chemical pesticides and can be deployed in urban areas, near schools, or in locations where mechanical removal is impractical.
Key features:
Research approach:
The technology is in early-stage development. Small-scale experiments have demonstrated that S. visci infection causes complete necrosis of mistletoe shrubs within a few months following inoculation. Initial culturing work has established suitable growth media and light conditions for sporulation, and spore viability and pathogenicity have been confirmed. Further development is needed to select optimal pathogen strains, scale up industrial biofermentation processes, develop formulation methods, and complete genome sequencing for patenting. The solution is not yet commercially available and requires additional validation and development before deployment.
University of Helsinki is a comprehensive public research university and Finland’s largest, serving as a multi-campus institution in the capital region with a strong international profile. Industry collaboration is enabled by shared core facilities and co-located laboratories, as well as a medical campus integrated with the regional university hospital for clinical translation and trials. Companies engage through contract research, sponsored access to instrumentation, and co-creation spaces near campus. Research is supported by competitive funding from the Research Council of Finland, Business Finland, and European programs including Horizon Europe and the European Research Council. A dedicated technology transfer company manages IP, licensing, and spinout formation to accelerate commercialization.